TG Therapeutics, Inc. (TGTX)

Several events have impacted TG Therapeutics' stock price in the past six months. In Q1 2026, the company reported earnings per share (EPS) of $0.12, missing the consensus estimate, but revenue reached $204.92 million, surpassing analyst estimates, and subsequently raised its full-year 2026 revenue target. The company released its Q4 2025 earnings on February 26, 2026, reporting an EPS of $0.14. Enrollment was completed in a Phase 3 trial for a subcutaneous formulation of BRIUMVI and the Phase 3B ENHANCE trial for intravenous (IV) BRIUMVI. TG Therapeutics refinanced an existing $250 million facility and secured a new five-year, $750 million term loan, resulting in $500 million in net cash and increasing its pro forma cash to approximately $700 million without equity dilution, and expanded its share buyback plans to $300 million. Analysts have issued various ratings and price target revisions, and the stock has seen a 17% increase since January, outperforming the S&P 500.

While TG Therapeutics has reported "12 consecutive quarters of sequential growth" for BRIUMVI, indicating strong and consistent demand, the company's management has also acknowledged "seasonal impacts and gross-to-net" as headwinds in Q1, suggesting some seasonal fluctuations in demand.

TG Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing novel treatments for B-cell mediated diseases. Their primary commercial product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). The company's development pipeline includes Ublituximab IV, TG-1701, TG-1801, and azer-cel, which is in a Phase 1 trial for progressive MS and is also being explored for other autoimmune indications.

TG Therapeutics generates the majority of its revenue from the sale of BRIUMVI in the United States, with additional revenue coming from the international market. The company's headquarters are located in Morrisville, North Carolina, United States.

TG Therapeutics has demonstrated strong commercial momentum for BRIUMVI, marked by record new patient enrollments and continuous market share gains, contributing to a generally positive analyst sentiment. However, BRIUMVI carries significant safety risks, including potential infusion reactions, serious infections, Progressive Multifocal Leukoencephalopathy (PML), and fetal harm, necessitating careful patient monitoring.

TG Therapeutics has significant institutional and insider ownership. Institutional shareholders collectively hold 67.38% of the company's shares, while insiders own 48.65%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, State Street Corp, Clearbridge Investments, LLC, Geode Capital Management, Llc, Soleus Capital Management, L.P., Congress Asset Management Co /ma, Goldman Sachs Group Inc, Pictet Asset Management Holding SA, and Invesco Ltd. Prominent individual insider owners include Michael S. Weiss, Ra Capital Management LP, Lindsay A. Md Rosenwald, Biotechnologies Sasu Lfb, and Joan Pons Gimbert.